Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.52 |
| ▸ | AHCY | P23526 | 4/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.48 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.47 |
| ▸ | AMD1 | P17707 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11703712 | 0.93 | ADORA2A (0.54) | ADORA2AADORA3AHCYHIF1ATMEM97 | |
| SCHEMBL3409898 | 0.92 | ADORA2A (0.53) | ADORA2AADORA3AHCYHIF1ATMEM97 | |
| SCHEMBL11701245 | 0.91 | ADORA2A (0.53) | ADORA2AADORA3AHCYHIF1ATMEM97 | |
| SCHEMBL7743648 | 0.89 | ADORA2A (0.40) | ADORA2AADORA3AHCYHIF1ATMEM97 | |
| SCHEMBL5987512 | 0.88 | TYMP (0.41) | ADORA2AADORA3AHCYHIF1ATMEM97 | |
| SCHEMBL3411985 | 0.88 | ADORA2A (0.53) | ADORA2AADORA3AHCYADORA2BHSP90B1 | |
| SCHEMBL6864727 | 0.87 | ADORA2A (0.54) | ADORA2AADORA3AHCYADORA2BHSP90B1 | |
| SCHEMBL6870926 | 0.85 | ADORA3 (0.44) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL10439705 | 0.85 | ADORA2A (0.54) | ADORA2AADORA3AHCYADORA2BKMT2A | |
| SCHEMBL6299609 | 0.84 | ADORA2A (0.54) | ADORA2AADORA3AHCYADORA2BTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY | 2018-12-06 | — | — | US | disclosed |
| WO-2016183217-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY (US) | 2016-11-17 | — | — | WO | disclosed |
| EP-1179050-B1 | METHOD FOR THE PURIFICATION OF PROTEIN KINASE BY AFFINITY CHROMATOGRAPHY | UNIV TARTU (EE) | 2012-12-19 | — | — | EP | disclosed |
| US-6903079-B2 | Nucleoside compounds and compositions thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-06-07 | — | — | US | disclosed |
| US-20030149050-A1 | Inhibitors of inflammation and reperfusion injury and methods of use thereof | INOTEK CORP. | 2003-08-07 | — | — | US | disclosed |
| US-6534651-B2 | Substituted isoindolinone derivatives | INOTEK PHARMACEUTICALS CORP. | 2003-03-18 | — | — | US | disclosed |
| US-20020095044-A1 | Inhibitors of inflammation and reperfusion injury and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2002-07-18 | — | — | US | disclosed |
| WO-2001077075-A2 | INHIBITORS OF INFLAMMATION AND REPERFUSION INJURY | INOTEK CORPORATION (US) | 2001-10-18 | — | — | WO | disclosed |
| EP-0708781-B1 | A 3 ADENOSINE RECEPTOR AGONISTS | USA (US) | 2001-10-04 | — | — | EP | disclosed |
| US-5773423-A | XANTHINE RIBOSIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-06-30 | — | — | US | disclosed |
| WO-1995002604-A1 | A3 ADENOSINE RECEPTOR AGONISTS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-01-26 | — | — | WO | disclosed |
| US-4167565-A | Adenosine-5'-carboxamides and method of use | ABBOTT LABORATORIES (US) | 1979-09-11 | — | — | US | disclosed |
| US-4029884-A | Adenosine-5'-carboxylic acid amides | ABBOTT LABORATORIES (US) | 1977-06-14 | — | — | US | disclosed |
| US-3971849-A | 1,N6 -etheno-5'-adenosine carboxylates for increasing coronary sinus partial pressure of oxygen | ABBOTT LABORATORIES (US) | 1976-07-27 | — | — | US | disclosed |
| US-3966917-A | ADENOSINE-5'-CARBOXAMIDES | ABBOTT LABORATORIES (US) | 1976-06-29 | — | — | US | disclosed |
| US-3931401-A | 1,N6 -etheno-5'-adenosine carboxamides for increasing coronary sinus partial pressure of oxygen | ABBOTT LABORATORIES (US) | 1976-01-06 | — | — | US | disclosed |
| US-3855204-A | PROCESS FOR PREPARING ADENOSINE-5{40 -CARBOXYLIC ACID, ETHYL ESTER | ABBOTT LAB | 1974-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020095044-A1 | Inhibitors of inflammation and reperfusion injury and methods of use thereof | IL1B, PTGS1, MMP8 | ADORA2A 211/4885ADORA3 780/4885AHCY 2416/4885 |
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | PHLPP1, PHLPP2, PLAA | ADORA2A 10/4885ADORA3 32/4885AHCY 567/4885 |
| US-20030149050-A1 | Inhibitors of inflammation and reperfusion injury and methods of use thereof | IL1B, PTGS1, MMP8 | ADORA2A 211/4885ADORA3 780/4885AHCY 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.